Loss of PDCD4 contributes to enhanced chemoresistance in Glioblastoma Multiforme through de-repression of Bcl-xL translation

Oncotarget

Volumn 4, Issue 9, 2013, Pages 1365-1372

  Liwak, Urszula ^a,b   Jordan, Lindsay E ^a,b   Von Holt, Sally Davidson ^c   Singh, Poonam ^c   Hanson, Jennifer E L ^d   Lorimer, Ian A ^b,d   Roncaroli, Federico ^c   Holcik, Martin ^a,b  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

ABT 737; Bcl xL; Glioblastoma multiforme; IRES; PDCD4; Translation initiation

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; DOXORUBICIN; PROGRAMMED CELL DEATH 4 PROTEIN; PROTEIN BCL XL; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIZATION; EMBRYO; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PROTEIN DEPLETION; PROTEIN EXPRESSION;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS REGULATORY PROTEINS; BCL-X PROTEIN; BIPHENYL COMPOUNDS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NITROPHENOLS; PIPERAZINES; PROTEIN BIOSYNTHESIS; RNA-BINDING PROTEINS; SULFONAMIDES;

EID: 84884699004     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1154     Document Type: Article

References (21)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109.
2. Preusser M, de Ribaupierre S, Wohrer A, Erridge SC, Hegi M, Weller M and Stupp R. Current concepts and management of glioblastoma. Ann Neurol. 2011; 70(1):9-21.
3. Gao F, Wang X, Zhu F, Wang Q, Zhang X, Guo C, Zhou C, Ma C, Sun W, Zhang Y, Chen YH and Zhang L. PDCD4 gene silencing in gliomas is associated with 5'CpG island methylation and unfavourable prognosis. J Cell Mol Med. 2009; 13(10):4257-4267.
4. Chen Y, Liu W, Chao T, Zhang Y, Yan X, Gong Y, Qiang B, Yuan J, Sun M and Peng X. MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G. Cancer letters. 2008; 272(2):197-205.
5. Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE and Pagano M. S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science. 2006; 314(5798):467-471.
6. Liwak U, Thakor N, Jordan LE, Roy R, Lewis SM, Pardo OE, Seckl M and Holcik M. Tumor suppressor PDCD4 represses internal ribosome entry site-mediated translation of antiapoptotic proteins and is regulated by S6 kinase 2. Molecular and cellular biology. 2012; 32(10):1818-1829.
7. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-674.
8. Lankat-Buttgereit B and Goke R. The tumour suppressor Pdcd4: recent advances in the elucidation of function and regulation. Biology of the cell / under the auspices of the European Cell Biology Organization. 2009; 101(6):309-317.
9. Singh P, Wedeken L, Waters LC, Carr MD and Klempnauer KH. Pdcd4 directly binds the coding region of c-myb mRNA and suppresses its translation. Oncogene. 2011; 30(49):4864-4873.
10. Wedeken L, Singh P and Klempnauer KH. Tumor suppressor protein Pdcd4 inhibits translation of p53 mRNA. J Biol Chem. 2011; 286(50):42855-42862.
11. Stegh AH and DePinho RA. Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma. Cell Cycle. 2011; 10(1):33-38.
12. Wang J, Beauchemin M and Bertrand R. Phospho-Bcl-x(L)(Ser62) plays a key role at DNA damage-induced G(2) checkpoint. Cell Cycle. 2012; 11(11):2159-2169.
13. Lu C and Shervington A. Chemoresistance in gliomas. Mol Cell Biochem. 2008; 312(1-2):71-80.
14. Gyrd-Hansen M and Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nature reviews Cancer. 2010; 10(8):561-574.
15. Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC and Fornace AJ, Jr. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer research. 2000; 60(21):6101-6110.
16. Cartron PF, Loussouarn D, Campone M, Martin SA and Vallette FM. Prognostic impact of the expression/phosphorylation of the BH3-only proteins of the BCL-2 family in glioblastoma multiforme. Cell Death Dis. 2012; 3:e421.
17. Charles NA, Holland EC, Gilbertson R, Glass R and Kettenmann H. The brain tumor microenvironment. Glia. 2011; 59(8):1169-1180.
18. Yoshimine S, Kikuchi E, Kosaka T, Mikami S, Miyajima A, Okada Y and Oya M. Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma. Br J Cancer. 2013; 108(11):2312-2320.
19. Gopinath S, Vanamala SK, Gujrati M, Klopfenstein JD, Dinh DH and Rao JS. Doxorubicin-mediated apoptosis in glioma cells requires NFAT3. Cell Mol Life Sci. 2009; 66(24):3967-3978.
20. Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R, Bayani J, Head R, Lee M, Bernstein M, Squire JA, Smith A and Dirks P. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell. 2009; 4(6):568-580.
21. Gont A, Restall IJ, Hanson JEL, Lavictoire SJ, Soucie M, Daneshmand M, Parolin DAE, Nicholas G, Woulfe J, Kassam A, Da Silva VF and Lorimer IAJ. PTEN loss represses glioblastoma tumor initiating cell differentiation via inactivation of Lgl1. Oncotarget. 2013. in press.